Background and Importance Pharmaceutical validation is necessary to achieve maximum clinical benefit. Thanks to clinical pharmaceutical interventions (CPI) many prescription errors, drug interactions and adverse reactions are prevented.
Aim and Objectives To analyse CPI carried in a 1040-bed hospital and to assess the acceptance rate of these interventions.
Material and Methods Observational and retrospective study of CPI performed between June and August 2022 in hospitalised patients. They were recorded in the pharmaceutical intervention module of PharmNet application of Millenium programme. The variables evaluated were: episode number, date, type of intervention, prescribing service, drug and indication. Interventions that led to a change in the prescription within 48 hours of the CPI were considered accepted.
Results A total of 324 interventions were analysed in 293 patients, which were 100% of those performed. More than half of the interventions were therapeutic duplications (36.4%; n=118) and dosing errors (25.9%; n=84) (overdose 62% and underdose 23%). They were followed in frequency by: incomplete medical orders (18.5%; n=60); drugs not indicated (6.8%; n=22); drug interactions (4.6%; n=15); inappropriate dosage form (4.6%; n=15) and adverse events (3%; n=10). The distribution of the number of interventions according to prescribing service was: cardiology (n=54); gastroenterology (n=44); pneumology (n=32); internal medicine (n=30); vascular medicine (n=29); neurology (n=23) and traumatology (n=28). The acceptance rate of the CPI was 80,3% (n=260) with the following service distribution: 90% internal medicine; 87.5% pneumology; 84% gastroenterology, 82.7% neurology and 79.3% cardiology. Drugs which caused most interventions were antibiotics (17%), anti-inflammatory drugs (11.4%), cardiovascular agents (11.1%) and antidepressants (9%).
Conclusion and Relevance The clinical pharmaceutical interventions proposed to the prescribing services were highly accepted. This shows the importance of pharmaceutical validation by the hospital pharmacist to better manage the quality and safety of pharmacological treatment prescribed to patients during their hospital stay.
Conflict of Interest No conflict of interest